Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo

Running trials

• Not yet recruiting

  Effect of Trimetazidine on Coronary Flow in Transthyretin Cardiac Amyloidosis

  NCT07836699· Phase 2· Fábio Fernandes· Source

• Recruiting

  Smartphone-Assisted Single-Session Psychotherapy Intervention for Postpartum Depression

  NCT07925762· University of Sao Paulo· Source

• Recruiting

  A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Inebilizumab in Children With Generalized Myasthenia Gravis (gMG)

  NCT06987539· Phase 2· Amgen· Source

• Recruiting

  A Clinical Study of MK-1045 in People With Non-Hodgkin Lymphoma (MK-1045-008)

  NCT07519772· Phase 1/2· Merck Sharp & Dohme LLC· Source

• Active, not recruiting

  Single-case Intervention Study for Visual Screening Assessment for Proof of Concept and Prediction of Clinical Response to Brexiprazole as Adjunctive Treatment in Adults With Major Depressive Disorder.

  NCT07723079· University of Sao Paulo· Source

• Recruiting

  A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 Diabetes

  NCT07351058· Phase 3· Hoffmann-La Roche· Source

• Recruiting

  A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes

  NCT07351045· Phase 3· Hoffmann-La Roche· Source

• Recruiting

  Lifestyle Intervention for Obesity and Eating Disorder Prevention in Transgender Adolescents

  NCT07466069· University of Sao Paulo· Source

• Recruiting

  A Study of Baricitinib (LY3009104) to Preserve Beta Cell Function in Children and Adults Newly Diagnosed With Type 1 Diabetes (BARICADE-PRESERVE)

  NCT07222332· Phase 3· Eli Lilly and Company· Source

• Recruiting

  A Study of Baricitinib (LY3009104) for the Delay of Stage 3 Type 1 Diabetes in At-Risk Children and Adults

  NCT07222137· Phase 3· Eli Lilly and Company· Source

• Recruiting

  A Study to Investigate the Efficacy and Safety of Fitusiran Prophylaxis in Male Participants Aged 1 to Less Than 12 Years With Hemophilia A or B

  NCT07285460· Phase 3· Sanofi· Source

• Recruiting

  Estradiol and Testosterone Subdermal Implants for Menopause Treatment (ESTIME)

  NCT06343870· Phase 3· University of Sao Paulo General Hospital· Source

• Recruiting

  A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)

  NCT07241390· Phase 3· Eli Lilly and Company· Source

• Recruiting

  A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)

  NCT07165028· Phase 3· Eli Lilly and Company· Source

• Recruiting

  Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)

  NCT07116967· Phase 3· Bristol-Myers Squibb· Source

• Recruiting

  A Study to Investigate Efficacy and Safety of Teplizumab Compared With Placebo in Participants 1 to 25 Years of Age With Stage 3 Type 1 Diabetes

  NCT07088068· Phase 3· Sanofi· Source

• Active, not recruiting

  A Clinical Study of MK-8527 to Prevent Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8527-011)

  NCT07044297· Phase 3· Merck Sharp & Dohme LLC· Source

• Recruiting

  A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease

  NCT06976216· Phase 3· Bristol-Myers Squibb· Source

• Recruiting

  A Study to Learn About the Effects of Felzartamab Infusions on Adults With Immunoglobulin A Nephropathy (IgAN)

  NCT06935357· Phase 3· Biogen· Source

• Active, not recruiting

  A Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or Overweight

  NCT06914895· Phase 3· Eli Lilly and Company· Source

• Recruiting

  A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)

  NCT06717347· Phase 3· Merck Sharp & Dohme LLC· Source

• Recruiting

  A Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Disease

  NCT06227910· Phase 3· Takeda· Source

• Recruiting

  A Study to Evaluate the Efficacy and Safety of Frexalimab, Brivekimig, or Rilzabrutinib in Participants Aged 16 to 75 Years With Primary Focal Segmental Glomerulosclerosis or Minimal Change Disease

  NCT06500702· Phase 2· Sanofi· Source

• Active, not recruiting

  Evaluation of Efficacy of Povetacicept in Adults With Immunoglobulin A Nephropathy (IgAN)

  NCT06564142· Phase 3· Alpine Immune Sciences Inc, A Subsidiary of Vertex· Source

• Active, not recruiting

  A Study to Test the Effects and Safety of Riliprubart in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) for Which the Usual Treatments do Not Work

  NCT06290128· Phase 3· Sanofi· Source

• Active, not recruiting

  A Study to Evaluate the Treatment Response and Safety of Two Dose Regimens of Subcutaneous Amlitelimab Compared With Treatment Withdrawal in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis

  NCT06407934· Phase 3· Sanofi· Source

• Active, not recruiting

  The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)

  NCT06383390· Phase 3· Eli Lilly and Company· Source

• Recruiting

  Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD)

  NCT05485961· Phase 2/3· CSL Behring· Source

• Recruiting

  Efficacy and Safety of CSL222 (Etranacogene Dezaparvovec) Gene Therapy in Adults With Hemophilia B With Pretreatment Adeno-associated Virus Serotype 5 (AAV5) Neutralizing Antibodies (Nabs)

  NCT06003387· Phase 3· CSL Behring· Source

• Active, not recruiting

  A Study to Test an Oral Medicine, Belumosudil, in Combination With Corticosteroids in Participants at Least 12 Years of Age With Newly Diagnosed Chronic Graft Versus Host Disease.

  NCT06143891· Phase 3· Sanofi· Source

• Enrolling by invitation

  Efficacy and Safety of Subcutaneous Dupilumab in Participants With Asthma/Asthmatic Wheeze Aged 2 to <6 Years (LIBERTY ASTHMA TREKIDS)

  NCT06191315· Phase 3· Sanofi· Source

• Recruiting

  MAGNITUDE: A Phase 3 Study of NTLA-2001 in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM)

  NCT06128629· Phase 3· Intellia Therapeutics· Source

• Recruiting

  A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell Lymphoma

  NCT06091865· Phase 3· Regeneron Pharmaceuticals· Source

• Recruiting

  A Long-Term Study of Elafibranor in Adult Participants With Primary Biliary Cholangitis

  NCT06016842· Phase 3· Ipsen· Source

• Enrolling by invitation

  A Study to Provide Access to Mitapivat for Participants Who Previously Participated in an Agios-Sponsored Mitapivat Study

  NCT05777993· Phase 4· Agios Pharmaceuticals, Inc.· Source

• Recruiting

  Study of Inebilizumab in Pediatric Subjects With Neuromyelitis Optica Spectrum Disorder

  NCT05549258· Phase 2· Amgen· Source

• Active, not recruiting

  A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities

  NCT05869903· Phase 3· Eli Lilly and Company· Source

• Enrolling by invitation

  International Treatment-extension Study in Adult Participants With Multiple Myeloma and Who Have Derived Clinical Benefit From Isatuximab

  NCT05669989· Phase 2· Sanofi· Source

• Active, not recruiting

  A Study to Investigate Subcutaneous Isatuximab in Combination With Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma

  NCT05704049· Phase 2· Sanofi· Source

• Recruiting

  Biperiden Trial for Epilepsy Prevention

  NCT04945213· Phase 3· Hospital Sirio-Libanes· Source

• Active, not recruiting

  A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity

  NCT05556512· Phase 3· Eli Lilly and Company· Source

• Recruiting

  A Phase 2/3 Study of Osivelotor in Adult and Adolescent Participants With SCD

  NCT05431088· Phase 2/3· Pfizer· Source

• Active, not recruiting

  Long-Term Safety and Efficacy Evaluation of Amlitelimab in Participants of Previous Amlitelimab Moderate to Severe Atopic Dermatitis Clinical Trials

  NCT05492578· Phase 2/3· Sanofi· Source

• Recruiting

  A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Obinutuzumab in Adolescents With Active Class III or IV Lupus Nephritis and the Safety and PK of Obinutuzumab in Pediatric Participants

  NCT05039619· Phase 2· Hoffmann-La Roche· Source

• Active, not recruiting

  A Study Evaluating the Efficacy and Safety of Mitapivat (AG-348) in Participants With Sickle Cell Disease (RISE UP)

  NCT05031780· Phase 2/3· Agios Pharmaceuticals, Inc.· Source

• Active, not recruiting

  Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Adult Patients With Uncontrolled Moderate to Severe Asthma

  NCT05097287· Phase 4· Sanofi· Source

• Active, not recruiting

  A Study to Test How Safe Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Alone Are and How Well They Work in Adult Patients With Generalized Myasthenia Gravis

  NCT05070858· Phase 3· Regeneron Pharmaceuticals· Source

• Active, not recruiting

  A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 )

  NCT04849728· Phase 3· Inventiva Pharma· Source

• Active, not recruiting

  Pre-Exposure Prophylaxis Study of Lenacapavir in Cisgender Men, Transgender Women, Transgender Men, and Gender Nonbinary People at Risk for HIV Infection

  NCT04925752· Phase 3· Gilead Sciences· Source

• Active, not recruiting

  Study to Evaluate Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

  NCT04384484· Phase 3· ADC Therapeutics S.A.· Source

Showing 50 of 56.

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Obesity3 recruiting
• Type 1 diabetes3 recruiting
• Type 2 diabetes3 recruiting
• Alzheimer disease2 recruiting
• Amyloidosis2 recruiting
• Chronic kidney disease2 recruiting
• Diffuse large B-cell lymphoma2 recruiting
• Haemophilia2 recruiting
• Asthma1 recruiting
• Cervical cancer1 recruiting
• Coronary artery disease1 recruiting
• Crohn's disease1 recruiting
• Epilepsy1 recruiting
• Fatty liver disease (MASLD/MASH)1 recruiting
• Follicular lymphoma1 recruiting
• Gestational diabetes1 recruiting
• Hodgkin lymphoma1 recruiting
• IgA nephropathy1 recruiting
• Lupus (SLE)1 recruiting
• Multiple myeloma1 recruiting
• Myasthenia gravis1 recruiting
• Nephrotic syndrome1 recruiting
• Neuromyelitis optica (NMOSD)1 recruiting
• Ovarian cancer1 recruiting
• Peripheral artery disease1 recruiting
• Primary biliary cholangitis1 recruiting
• Psoriasis1 recruiting
• Sickle cell disease1 recruiting
• Stroke1 recruiting
• Thalassaemia1 recruiting

Closed trials

• Withdrawn

  Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Adults at High Risk of Delayed Graft Function (DGF) Following Kidney Allograft Transplantation

  NCT07020832· Phase 3· Apellis Pharmaceuticals, Inc.· Source

• Completed

  A Master Protocol for Orforglipron in Participants With Obstructive Sleep Apnea and Obesity or Overweight

  NCT06649045· Phase 3· Eli Lilly and Company· Source

• Completed

  ACT for Syndromic and Subsyndromic Depression in Bipolar Disorder

  NCT06365021· Beny Lafer· Source

• Completed

  A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis on Background Topical Corticosteroids

  NCT06224348· Phase 3· Sanofi· Source

• Completed

  A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With Placebo in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis

  NCT06130566· Phase 3· Sanofi· Source

• Terminated

  Study of Daxdilimab (HZN-7734) in Participants With Active Proliferative Lupus Nephritis (LN)

  NCT05540665· Phase 2· Amgen· Source

• Completed

  A Study to Evaluate Rocatinlimab (AMG 451) in Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD)

  NCT05704738· Phase 3· Amgen· Source

• Completed

  Endoscopic Gastric Mucosal Ablation (GMA) of Class III Obesity

  NCT05574777· Erbe Elektromedizin GmbH· Source

• Completed

  A Study to Evaluate the Efficacy and Safety of Obinutuzumab Versus MMF in Participants With Childhood Onset Idiopathic Nephrotic Syndrome

  NCT05627557· Phase 3· Hoffmann-La Roche· Source

• Completed

  A Study to Explore Treatment Patterns, Treatment Outcomes, Healthcare Resource Utilization in Adult Participants With Myelofibrosis Through Chart Review

  NCT05444972· AbbVie· Source

• Completed

  Obstructive Sleep Apnea Master Protocol GPIF: A Study of Tirzepatide (LY3298176) in Participants With Obstructive Sleep Apnea

  NCT05412004· Phase 3· Eli Lilly and Company· Source

• Terminated

  Resolution of Sickle Cell Leg Ulcers With Voxelotor

  NCT05561140· Phase 3· Pfizer· Source

• Completed

  Clinical Trial of Iclepertin Effect on Cognition and Functional Capacity in Schizophrenia (CONNEX-2)

  NCT04846881· Phase 3· Boehringer Ingelheim· Source

• Completed

  EFFECT OF ADDING DAPAGLIFLOZIN TO ALLOGRAFT DYSFUNCTION OF RENAL TRANSPLANTED PATIENTS.

  NCT04743453· Phase 4· University of Sao Paulo General Hospital· Source

• Completed

  A Study to Learn About the Long-Term Safety of Higher Doses of Nusinersen (BIIB058) Given as Injections to Participants With Spinal Muscular Atrophy (SMA) Who Took Part in an Earlier Nusinersen Trial (ONWARD)

  NCT04729907· Phase 3· Biogen· Source

• Completed

  Study to Evaluate the Efficacy and Safety of Valoctocogene Roxaparvovec, With Prophylactic Steroids in Hemophilia A

  NCT04323098· Phase 3· BioMarin Pharmaceutical· Source

• Completed

  A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes

  NCT04255433· Phase 3· Eli Lilly and Company· Source

• Completed

  A Study to Evaluate the Safety and Efficacy of Polatuzumab Vedotin in Combination With Rituximab, Gemcitabine and Oxaliplatin Compared to Rituximab, Gemcitabine and Oxaliplatin Alone in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

  NCT04182204· Phase 3· Hoffmann-La Roche· Source

• Completed

  Optimal Blood Pressure for the prevenTIon of Major vAscuLar Events in Patients With DIABETES Mellitus (OPTIMAL-DIABETES)

  NCT04040634· Hospital Israelita Albert Einstein· Source

• Completed

  Optimal Blood Pressure for the prevenTIon of Major vAscuLar Events in Stroke Patients

  NCT04036409· Hospital Israelita Albert Einstein· Source

• Completed

  A Study to Evaluate Prospective Efficacy and Safety Data of Current FIX Prophylaxis Replacement Therapy in Adult Hemophilia B Subjects (FIX:C≤2%) or Current FVIII Prophylaxis Replacement Therapy in Adult Hemophilia A Subjects (FVIII:C≤1%)

  NCT03587116· Phase 3· Pfizer· Source

• Completed

  This is an Extension Study of the Roche P-trials to Investigate Safety and Effectiveness of Ocrelizumab in Participants With Multiple Sclerosis (MS)

  NCT03599245· Phase 3· Hoffmann-La Roche· Source

• Completed

  A Study Comparing the Efficacy and Safety of Polatuzumab Vedotin With Rituximab-Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab-Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Diffuse Large B-Cell Lymphoma

  NCT03274492· Phase 3· Hoffmann-La Roche· Source

• Completed

  Investigate Safety, Tolerability, PK, PD and Efficacy of Risdiplam (RO7034067) in Infants With Type1 Spinal Muscular Atrophy

  NCT02913482· Phase 2· Hoffmann-La Roche· Source

• Completed

  Stem Cell Transplantation With NiCord® (Omidubicel) vs Standard UCB in Patients With Leukemia, Lymphoma, and MDS

  NCT02730299· Phase 3· Gamida Cell ltd· Source

• Completed

  A Randomized Controlled Trial of TNK-tPA Versus Standard of Care for Minor Ischemic Stroke With Proven Occlusion

  NCT02398656· Phase 3· University of Calgary· Source

• Completed

  Comparison of the Treatments of Obinutuzumab + Venetoclax Versus Obinutuzumab + Chlorambucil in Patients With Chronic Lymphocytic Leukemia

  NCT02242942· Phase 3· Hoffmann-La Roche· Source

• Recruiting

  Pompe Disease Registry Protocol

  NCT00231400· Genzyme, a Sanofi Company· Source

• Recruiting

  International Collaborative Gaucher Group (ICGG) Gaucher Disease Registry & Pregnancy Sub-registry

  NCT00358943· Genzyme, a Sanofi Company· Source

Conditions

Diseases this institution publishes on or runs trials for.

• Lupus (SLE)24 works · 3 trials
• Pulmonary arterial hypertension22 works · 0 trials
• Obstructive sleep apnoea18 works · 2 trials
• Systemic sclerosis (scleroderma)11 works · 0 trials
• Frontotemporal dementia8 works · 0 trials
• Hydrocephalus8 works · 0 trials
• Dystonia7 works · 0 trials
• Ankylosing spondylitis7 works · 0 trials
• Wilson disease7 works · 0 trials
• Hyperparathyroidism6 works · 0 trials
• Pituitary tumours5 works · 0 trials
• Uterine fibroids4 works · 0 trials
• Cushing's syndrome4 works · 0 trials
• Optic neuritis4 works · 0 trials
• Antiphospholipid syndrome4 works · 0 trials